BACKGROUND:The efficacy of doxycycline for treating the causal agent of human lymphatic filariasis, Brugia malayi, is unknown. Standard treatment with diethylcarbamazine-albendazole is associated with adverse reactions. We assessed whether doxycycline alone or in combination with diethylcarbamazine-albendazole would lead to sustained amicrofilaremia and reduced incidence of adverse reactions. METHODS:A double-blind, randomized, placebo-controlled 6-week field trial of doxycycline treatment (100 mg/day) of 161 persons infected with B. malayi was conducted. Four months after receiving doxycycline (n=119) or placebo (n=42), participants received diethylcarbamazine (6 mg/kg) plus albendazole (400 mg) or a matching placebo. Adverse reactions were assessed 48 and 60 h after administration of diethylcarbamazine-albendazole. Treatment efficacy was evaluated at 2, 4, and 12 months after the initial doxycycline treatment. RESULTS:Four months after beginning doxycycline treatment, Wolbachia loads were reduced by 98%. Doxycycline treatment reduced the prevalence of microfilaremia at 2, 4, and 12 months of follow-up (P<.001 for all time points). At the 1-year follow-up, prevalence was reduced by 77% and 87.5% in patients receiving doxycycline alone or doxycycline plus diethylcarbamazine-albendazole, respectively. In contrast, the reduction of microfilaremia in the group receiving placebo doxycycline plus diethylcarbamazine-albendazole was merely 26.7%. Adverse reactions were lowest in the group receiving doxycycline plus placebo diethylcarbamazine-albendazole and highest in the group receiving placebo doxycycline plus diethylcarbamazine-albendazole. The proportion of persons with high fever and severe adverse reactions was significantly reduced in the group treated with doxycycline plus diethylcarbamazine-albendazole. CONCLUSIONS:A 6-week course of doxycycline, either alone or in combination with diethylcarbamazine-albendazole, leads to a decrease in microfilaremia and reduces adverse reactions to antifilarial treatment in B. malayi-infected persons.

译文

背景:强力霉素对人类淋巴丝虫病的致病因子马来氏丝瓜病的疗效尚不清楚。二乙基卡巴马嗪-阿苯达唑的标准治疗与不良反应有关。我们评估了多西环素单独使用还是与二乙基卡巴马嗪-阿苯达唑合用会导致持续的微丝血症和不良反应的发生率降低。
方法:进行了一项双盲,随机,安慰剂对照的为期6周的强力霉素治疗(100毫克/天)的六周野外试验,该试验对161名感染了马来芽孢杆菌的人进行了研究。接受强力霉素(n = 119)或安慰剂(n = 42)四个月后,参与者接受了二乙基卡巴嗪(6 mg / kg)加阿苯达唑(400 mg)或匹配的安慰剂。给予二乙基卡巴嗪-阿苯达唑后48和60小时评估不良反应。在初始多西环素治疗后第2、4和12个月评估治疗效果。
结果:开始使用强力霉素治疗四个月后,Wolbachia负荷降低了98%。多西环素治疗在随访的2、4和12个月时降低了微丝虫病的发生率(所有时间点P均<.001)。在为期1年的随访中,单独接受强力霉素或强力霉素加二乙基卡巴嗪-阿苯达唑治疗的患者的患病率分别降低了77%和87.5%。相比之下,接受安慰剂多西环素加二乙基卡巴马嗪-阿苯达唑的组中的微丝血症减少仅26.7%。接受多西环素加安慰剂二乙基卡巴马嗪-阿苯达唑组的不良反应最低,接受安慰剂多西环素加二乙基卡巴马嗪-阿苯达唑组的不良反应最高。强力霉素加二乙基卡巴马嗪-阿苯达唑治疗组的高烧和严重不良反应患者的比例显着降低。
结论:强力霉素的6周疗程,单独或与二乙基卡巴马嗪-阿苯达唑合用,可降低微丝血症,并减少感染马来芽孢杆菌的人的抗丝虫治疗不良反应。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录